ClinicalTrials.gg
RecruitingNCT07465653Updated Nov 12, 2026

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

A Phase 1 interventional study of HJB647 low dose and HJB647 high dose in Heart Failure With Reduced Ejection Fraction, sponsored by Novartis Pharmaceuticals. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 74 studies in Heart Failure by Novartis — 4 open to participants now, 4 under way, 2 of them phase 3. Heart Failure · Novartis.

Planned enrollment
50th of 54
12 · median 209
Started
2026
with 1 other
Phase 1
2 of 74
1 open now
Registered
72nd of 74
by date

Among the 74 studies in Heart Failure by Novartis, this one is the 50th largest by planned enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 72nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 74 studies in Heart Failure by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Heart Failure by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

Read the detailed description

This is a multi-center, randomized, participant- and investigator- blinded, placebo- controlled crossover study to investigate the safety, tolerability, and pharmacokinetics of HJB647 in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

The study will consist of approximately 12 participants randomly assigned in a 1:1:1 ratio to one of three 3-day treatment sequences comprised of two doses of HJB647 and placebo. Dosing of the HJB647 and placebo is planned for 3 consecutive days. Participants will be domiciled during study drug administration period for close monitoring with a follow-up in-clinic visit on Day 7. A safety call will be performed on Day 33.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • Sacubitril
  • Valsartan
  • Heart failure
  • Cardiac Failure
  • Myocardial Failure
  • Heart failure with reduced ejection fraction
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  • Men and women aged 18 years or older
  • Stable functional class II-III
  • \<50%
  • NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening
  • On stable standard of care therapy with sacubitril/valsartan for at least 4 weeks before screening.

Exclusion criteria

Exclusion Criteria:

Participants will be deemed ineligible for inclusion if they meet any of the following exclusion criteria:

  • Acute decompensated heart failure within 3 months prior to screening
  • SBP \<105 mmHg at screening or baseline.
  • Acute coronary syndrome, stroke, , cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening
  • Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening
  • \<30 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula
  • >40 kg/m2
  • Strong inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products
  • Women of

Further eligibility criteria might apply in alignment with the trial protocol.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Taken by mouth as capsules

    Other: Placebo

  • Experimental
    HJB647 low dose

    Taken by mouth as capsule

    Drug: HJB647 low dose

  • Experimental
    HJB647 high dose

    Taken by mouth as capsule

    Drug: HJB647 high dose

Interventions

  • DrugHJB647 low dose

    Study drug low dose in capsule form

  • DrugHJB647 high dose

    Study drug high dose in capsule form

  • OtherPlacebo

    Placebo control in capsule form

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Number of participants with AEs as a measure of safety and tolerability

    Time frame: Up to 33 days

  2. Number of participants with clinically significant changes in vital signs

    Number of participants with clinically significant changes in Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate, Electrocardiogram and hyposensitive events as a measure of adverse events

    Time frame: Up to 33 days

Secondary outcomes

  1. Pharmacokinetics: Maximum concentration (Cmax)

    Maximum concentration (Cmax) of the trial drug in participants' blood

    Time frame: Up to 7 days

  2. Pharmacokinetics: Time to reach maximum plasma concentration (Tmax)

    Time to require the trial drug to reach its maximum concentration in participants blood

    Time frame: Up to 7 days

  3. Pharmacokinetics: Area Under the Concentration-Time Curve from dosing form to the last measurable concentration (AUClast)

    Area under the curve from time zero to the last measurable concentration sampling time

    Time frame: Up to 7 days

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 8 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 12, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Dec 8, 2026was Sep 2026
CompletionEst.
Dec 8, 2026was Sep 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Novartis Investigative Site · Sherbrooke, Canada
Nov 12, 2026
Primary completion
Sep 24, 2026→Dec 8, 2026
Oct 1, 2026
Study completion
Sep 24, 2026→Dec 8, 2026
Oct 1, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedOn stable standard of care therapy with sacubitril/valsartan with a dose of at least 49/51 mg BID for at least 4 weeks before screening.
Oct 1, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • Novartis Investigative Site · Sherbrooke, Canada
    + 1 other change: verification date
  2. Oct 1, 2026
    Primary completion Sep 24, 2026→Dec 8, 2026
    Study completion Sep 24, 2026→Dec 8, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedOn stable standard of care therapy with sacubitril/valsartan with a dose of at least 49/51 mg BID for at least 4 weeks before screening.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07465653
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 18, 2026
Primary completion
Dec 8, 2026 (estimated)
Completion
Dec 8, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion